Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Facon, Thierry | - |
dc.contributor.author | Lee, Jae Hoon | - |
dc.contributor.author | Moreau, Philippe | - |
dc.contributor.author | Niesvizky, Ruben | - |
dc.contributor.author | Dimopoulos, Meletios | - |
dc.contributor.author | Hajek, Roman | - |
dc.contributor.author | Pour, Ludek | - |
dc.contributor.author | Jurczyszyn, Artur | - |
dc.contributor.author | Qiu, Lugui | - |
dc.contributor.author | Klippel, Zandra | - |
dc.contributor.author | Zahlten-Kumeli, Anita | - |
dc.contributor.author | Osman, Muhtarjan | - |
dc.contributor.author | Paiva, Bruno | - |
dc.contributor.author | San-Miguel, Jesus | - |
dc.date.available | 2020-02-27T03:41:09Z | - |
dc.date.created | 2020-02-04 | - |
dc.date.issued | 2019-05-02 | - |
dc.identifier.issn | 0006-4971 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/1487 | - |
dc.description.abstract | The phase 3 CLARION study compared carfilzomib-melphalan-prednisone (KMP) with bortezomib-melphalan-prednisone (VMP) in transplant-ineligible newly diagnosed multiple myeloma (NDMM) patients. Patients were randomized 1: 1 to KMP or VMP for nine 42-day cycles (C). Patients received carfilzomib on days (D) 1, 2, 8, 9, 22, 23, 29, 30 (20 mg/m(2): C1D1, C1D2; 36 mg/m(2) thereafter) or bortezomib on D1, 4, 8, 11, 22, 25, 29, 32 (1.3 mg/m(2); D4, 11, 25, 32 omitted for C5-9). Melphalan (9 mg/m(2)) and prednisone (60 mg/m(2)) were administered on D1-4. The primary endpoint was progression-free survival (PFS). Nine hundred fifty-five patients were randomized (intention-to-treat population: KMP, n = 478; VMP, n = 477). Median PFS was 22.3 months with KMP vs 22.1 months with VMP (hazard ratio [HR], 0.906; 95% confidence interval [CI], 0.746-1.101; P = .159). Median overall survival was similar and not reached in either group (HR, 1.08; 95% CI, 0.82-1.43). Overall response rate was 84.3% for KMP and 78.8% for VMP. Complete response rate was 25.9% for KMP and 23.1% for VMP. Minimal residual disease-negative rates were 15.7% (KMP) and 15.5% (VMP). Adverse events (AEs) of interest (any grade) occurring with a >= 5% higher patient incidence in the KMP arm were acute renal failure (13.9% [KMP] vs 6.2% [VMP]) and cardiac failure (10.8% vs 4.3%). Grade >= 3 AE rates were 74.7% (KMP) and 76.2% (VMP). Grade >= 2 peripheral neuropathy was lower for KMP vs VMP (2.5% vs 35.1%). Treatment with KMP in CLARION did not yield a statistically significant difference in PFS vs VMP. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | AMER SOC HEMATOLOGY | - |
dc.relation.isPartOf | BLOOD | - |
dc.subject | QUALITY-OF-LIFE | - |
dc.subject | PLUS MELPHALAN | - |
dc.subject | DEXAMETHASONE | - |
dc.subject | LENALIDOMIDE | - |
dc.subject | SURVIVAL | - |
dc.subject | THERAPY | - |
dc.subject | RISK | - |
dc.title | Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000466711200006 | - |
dc.identifier.doi | 10.1182/blood-2018-09-874396 | - |
dc.identifier.bibliographicCitation | BLOOD, v.133, no.18, pp.1953 - 1963 | - |
dc.identifier.scopusid | 2-s2.0-85065589424 | - |
dc.citation.endPage | 1963 | - |
dc.citation.startPage | 1953 | - |
dc.citation.title | BLOOD | - |
dc.citation.volume | 133 | - |
dc.citation.number | 18 | - |
dc.contributor.affiliatedAuthor | Lee, Jae Hoon | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | QUALITY-OF-LIFE | - |
dc.subject.keywordPlus | PLUS MELPHALAN | - |
dc.subject.keywordPlus | DEXAMETHASONE | - |
dc.subject.keywordPlus | LENALIDOMIDE | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | RISK | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.